Segment Reporting - Summary of Operating Costs and Expenses (Parenthetical) (Details) - USD ($) $ in Thousands |
3 Months Ended | |
|---|---|---|
Mar. 31, 2025 |
Mar. 31, 2024 |
|
| Segment Reporting Information [Line Items] | ||
| Amortization expense | $ 342 | $ 0 |
| Depreciation expense | 7 | 7 |
| Research and Development | ||
| Segment Reporting Information [Line Items] | ||
| Share-based payment expense | 19 | 96 |
| Depreciation expense | 3 | 4 |
| General and Administration | ||
| Segment Reporting Information [Line Items] | ||
| Share-based payment expense | 42 | 42 |
| Depreciation expense | 4 | $ 3 |
| Pfizer Intangible Asset | ||
| Segment Reporting Information [Line Items] | ||
| Amortization expense | $ 342 | |
| X | ||||||||||
- Definition Amount of expense for award under share-based payment arrangement. Excludes amount capitalized. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|